How I treat infant leukemia

Patrick Brown, Rob Pieters, Andrea Biondi

Research output: Contribution to journalArticle

Abstract

Leukemia in infants is rare but generates tremendous interest due to its aggressive clinical presentation in a uniquely vulnerable host, its poor response to current therapies, and its fascinating biology. Increasingly, these biological insights are pointing the way toward novel therapeutic approaches. Using representative clinical case presentations, we review the key clinical, pathologic, and epidemiologic features of infant leukemia, including the high frequency of KMT2A gene rearrangements. We describe the current approach to risk-stratified treatment of infant leukemia in the major international cooperative groups. We highlight recent discoveries that elucidate the molecular biology of infant leukemia and suggest novel targeted therapeutic strategies, including modulation of aberrant epigenetic programs, inhibition of signaling pathways, and immunotherapeutics. Finally, we underscore the need for increased global

collaboration to translate these discoveries into improved outcomes.

Original languageEnglish (US)
Pages (from-to)205-214
Number of pages10
JournalBlood
Volume133
Issue number3
DOIs
StatePublished - Jan 17 2019

Fingerprint

Molecular biology
Leukemia
Genes
Modulation
Gene Rearrangement
Therapeutics
Epigenomics
Molecular Biology

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Brown, P., Pieters, R., & Biondi, A. (2019). How I treat infant leukemia. Blood, 133(3), 205-214. https://doi.org/10.1182/blood-2018-04-785980

How I treat infant leukemia. / Brown, Patrick; Pieters, Rob; Biondi, Andrea.

In: Blood, Vol. 133, No. 3, 17.01.2019, p. 205-214.

Research output: Contribution to journalArticle

Brown, P, Pieters, R & Biondi, A 2019, 'How I treat infant leukemia', Blood, vol. 133, no. 3, pp. 205-214. https://doi.org/10.1182/blood-2018-04-785980
Brown, Patrick ; Pieters, Rob ; Biondi, Andrea. / How I treat infant leukemia. In: Blood. 2019 ; Vol. 133, No. 3. pp. 205-214.
@article{35e210dfbada4293b601dff30c9724a5,
title = "How I treat infant leukemia",
abstract = "Leukemia in infants is rare but generates tremendous interest due to its aggressive clinical presentation in a uniquely vulnerable host, its poor response to current therapies, and its fascinating biology. Increasingly, these biological insights are pointing the way toward novel therapeutic approaches. Using representative clinical case presentations, we review the key clinical, pathologic, and epidemiologic features of infant leukemia, including the high frequency of KMT2A gene rearrangements. We describe the current approach to risk-stratified treatment of infant leukemia in the major international cooperative groups. We highlight recent discoveries that elucidate the molecular biology of infant leukemia and suggest novel targeted therapeutic strategies, including modulation of aberrant epigenetic programs, inhibition of signaling pathways, and immunotherapeutics. Finally, we underscore the need for increased globalcollaboration to translate these discoveries into improved outcomes.",
author = "Patrick Brown and Rob Pieters and Andrea Biondi",
year = "2019",
month = "1",
day = "17",
doi = "10.1182/blood-2018-04-785980",
language = "English (US)",
volume = "133",
pages = "205--214",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - How I treat infant leukemia

AU - Brown, Patrick

AU - Pieters, Rob

AU - Biondi, Andrea

PY - 2019/1/17

Y1 - 2019/1/17

N2 - Leukemia in infants is rare but generates tremendous interest due to its aggressive clinical presentation in a uniquely vulnerable host, its poor response to current therapies, and its fascinating biology. Increasingly, these biological insights are pointing the way toward novel therapeutic approaches. Using representative clinical case presentations, we review the key clinical, pathologic, and epidemiologic features of infant leukemia, including the high frequency of KMT2A gene rearrangements. We describe the current approach to risk-stratified treatment of infant leukemia in the major international cooperative groups. We highlight recent discoveries that elucidate the molecular biology of infant leukemia and suggest novel targeted therapeutic strategies, including modulation of aberrant epigenetic programs, inhibition of signaling pathways, and immunotherapeutics. Finally, we underscore the need for increased globalcollaboration to translate these discoveries into improved outcomes.

AB - Leukemia in infants is rare but generates tremendous interest due to its aggressive clinical presentation in a uniquely vulnerable host, its poor response to current therapies, and its fascinating biology. Increasingly, these biological insights are pointing the way toward novel therapeutic approaches. Using representative clinical case presentations, we review the key clinical, pathologic, and epidemiologic features of infant leukemia, including the high frequency of KMT2A gene rearrangements. We describe the current approach to risk-stratified treatment of infant leukemia in the major international cooperative groups. We highlight recent discoveries that elucidate the molecular biology of infant leukemia and suggest novel targeted therapeutic strategies, including modulation of aberrant epigenetic programs, inhibition of signaling pathways, and immunotherapeutics. Finally, we underscore the need for increased globalcollaboration to translate these discoveries into improved outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85060153756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060153756&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-04-785980

DO - 10.1182/blood-2018-04-785980

M3 - Article

C2 - 30459160

AN - SCOPUS:85060153756

VL - 133

SP - 205

EP - 214

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -